Who are rMenB+OMV NZ vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Meningococcal B, Licensed 4CMenB vaccine, Meningococcal vaccine GSK134612, MenBvac, Bexsero® vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rmenb-omv-nz-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

rMenB+OMV NZ vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

rMenB+OMV NZ vaccine (rMenB+OMV NZ vaccine) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Meningococcal serogroup B vaccine. Area: Immunology / Infectious Disease.

marketed Meningococcal serogroup B vaccine Neisseria meningitidis serogroup B surface antigens Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

rMenB+OMV NZ vaccine (rMenB+OMV NZ vaccine) — GlaxoSmithKline. This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B by combining recombinant meningococcal protein antigens with outer membrane vesicles from a New Zealand strain.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
rMenB+OMV NZ vaccine TARGET	rMenB+OMV NZ vaccine	GlaxoSmithKline	marketed	Meningococcal serogroup B vaccine	Neisseria meningitidis serogroup B surface antigens
Meningococcal B	Meningococcal B	Canadian Immunization Research Network	marketed	vaccine	Neisseria meningitidis serogroup B surface antigens (recombinant proteins)
Licensed 4CMenB vaccine	Licensed 4CMenB vaccine	University of Adelaide	marketed	Recombinant protein vaccine	Neisseria meningitidis serogroup B surface antigens
Meningococcal vaccine GSK134612	Meningococcal vaccine GSK134612	GlaxoSmithKline	phase 3	Recombinant protein vaccine	Neisseria meningitidis serogroup B surface antigens
MenBvac	MenBvac	University Hospital, Rouen	phase 3	Vaccine	Neisseria meningitidis serogroup B surface antigens
Bexsero® vaccine	Bexsero® vaccine	ANRS, Emerging Infectious Diseases	phase 3	Recombinant protein vaccine	Neisseria meningitidis serogroup B surface antigens (fHbp, NHBA, NadA, PorA)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Meningococcal serogroup B vaccine class)

GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rMenB+OMV NZ vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/rmenb-omv-nz-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab